Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Kala Pharmaceuticals, Inc. | kala-20191231x10k.htm |
| EX-32.2 - EX-32.2 - Kala Pharmaceuticals, Inc. | kala-20191231ex322c2f60a.htm |
| EX-32.1 - EX-32.1 - Kala Pharmaceuticals, Inc. | kala-20191231ex3215debf5.htm |
| EX-31.2 - EX-31.2 - Kala Pharmaceuticals, Inc. | kala-20191231ex312f959a3.htm |
| EX-31.1 - EX-31.1 - Kala Pharmaceuticals, Inc. | kala-20191231ex311177fb3.htm |
| EX-21.1 - EX-21.1 - Kala Pharmaceuticals, Inc. | kala-20191231ex21156cbf0.htm |
| EX-4.3 - EX-4.3 - Kala Pharmaceuticals, Inc. | kala-20191231ex439fe4e65.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement No. 333-226748 on Form S-3 and Nos. 333-219403,333-224083 and 333-230206 on Form S-8 of our report dated February 12, 2020, relating to the consolidated financial statements of Kala Pharmaceuticals, Inc. and its subsidiaries appearing in the Annual Report on Form 10-K of Kala Pharmaceuticals, Inc. for the year ended December 31, 2019.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
February 12, 2020